Skip to main content
57°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
160.81
-0.91 (-0.56%)
Official Closing Price
Updated: 6:30 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
AbbVie's Options Frenzy: What You Need to Know
January 12, 2024
Via
Benzinga
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
January 11, 2024
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.
Via
Benzinga
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing...
Via
Benzinga
Exposures
Product Safety
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
January 11, 2024
Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 10, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
January 09, 2024
Via
Benzinga
Big Players' Recent Trades in ABBV Options
January 05, 2024
Via
Benzinga
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
January 02, 2024
Via
Investor Brand Network
3 Simple Tricks That Every Investor Should Use (but Most Don't)
January 09, 2024
Having a few tricks up your sleeve can increase your returns over time.
Via
The Motley Fool
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
January 08, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted.
Via
Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
January 07, 2024
You should do your best to avoid making similar mistakes too.
Via
The Motley Fool
Peering Into AbbVie's Recent Short Interest
December 29, 2023
Via
Benzinga
Is AbbVie Stock a Buy Now?
January 07, 2024
The company is grappling with losing Humira's patent protection in 2023.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
24 Top Dividend Stocks to Buy and Hold in 2024
January 07, 2024
These stocks could deliver positive gains in the new year -- but the real money-making opportunities are over the next decade and beyond.
Via
The Motley Fool
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
January 06, 2024
There's more than meets the eye with all three of these dividend stocks.
Via
The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
1 Concerning Trend for AbbVie Investors to Keep an Eye On
January 03, 2024
Is AbbVie a good stock for dividend investors to own?
Via
The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
January 02, 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
January 02, 2024
The types of innovative drugs these companies develop are always in high demand.
Via
The Motley Fool
3 Top Dividend Growth Stocks to Buy in 2024
January 02, 2024
Income investors should love these great stocks.
Via
The Motley Fool
The 3 Hottest Dividend Stocks to Watch in 2024
January 01, 2024
With 2023 in the books and the entirety of 2024 ahead of us, here are compelling dividend stocks to watch for astute investors.
Via
InvestorPlace
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
January 01, 2024
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with.
Via
The Motley Fool
Topics
ETFs
Retirement
Exposures
Pension
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
December 31, 2023
Getting going on investing is a terrific way to start 2024.
Via
The Motley Fool
4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024
December 31, 2023
These companies pay attractive dividends that should continue rising.
Via
The Motley Fool
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Common Investing Mistake: Income Obsession (& More)
December 28, 2023
A common investing mistake is income obsession. Others are holding too many stocks and focusing on valuation to know if the price of a stock is right. Sounds familiar? Any of these mistakes hurts your...
Via
Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
December 26, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
60
61
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.